查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924997

全球移植診斷市場預測至2032年：按檢測類型、生物標記類型、移植類型、應用、最終用戶和地區分類

Transplant Diagnostics Market Forecasts to 2032 - Global Analysis By Test Type (Molecular Assays, Non-Molecular Assays, and Sequencing-based Molecular Assays), Biomarker Type, Transplant Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計 2025 年全球移植診斷市場規模將達到 69.9 億美元，到 2032 年將達到 131.1 億美元，預測期內複合年成長率為 9.4%。

移植診斷是一個專注於檢測和監測移植器官和組織健康狀況及相容性的醫學領域。這包括確認捐贈者與受體相容性的檢測、追蹤器官功能以及及早識別潛在的排斥反應和感染疾病。透過準確快速的評估，該領域幫助醫療服務提供者改善患者預後、延長移植器官壽命並最大限度地減少併發症。

根據美國衛生資源與服務管理局 (HRSA) 的數據，截至 2024 年 3 月，美國已進行了超過 46,000 例器官移植手術。

慢性病發生率呈上升趨勢

醫療機構正在尋求先進的檢測方法，以最佳化供體與受體的匹配，並改善患者預後。分子和免疫學檢測技術的創新使得移植併發症的早期發現成為可能。人口老化和合併症發生率的上升，凸顯了移植後診斷監測的必要性。醫院和專科診所正在部署尖端的診斷平台，以降低排斥反應的風險。個人化醫療的進步推動了為每位患者客製化診斷方案的應用。總體而言，慢性病盛行率的快速成長正在加速先進移植診斷解決方案的普及應用。

器官短缺缺口

器官供應有限給診斷流程帶來了越來越大的壓力，而提高移植成功率至關重要。監管障礙和嚴格的倫理準則進一步加劇了捐贈者配對過程的複雜性。資源限制往往限制新興市場小規模實驗室和機構採用先進檢測方法。新診斷試劑盒漫長的核准流程也延緩了其臨床應用。儘管臨床需求迫切，但這些限制因素可能會阻礙對創新技術的投資。因此，器官供需之間的差距持續限制移植診斷市場的擴張。

人工智慧和機器學習

預測演算法可以增強供體-受體相容性評估並預測移植存活率。自動化數據分析可減少診斷錯誤，並加快移植中心的決策速度。機器學習模型正擴大應用於解讀複雜的免疫學和基因組資料集。人工智慧驅動平台的應用使檢查室能夠在提高效率的同時降低營運成本。基於雲端的分析有助於跨多個機構對移植患者進行即時監測。預計這一趨勢將透過實現精準醫療和預測性護理解決方案，徹底改變移植診斷方式。

倫理和資料隱私問題

處理敏感的基因組和免疫學資訊需要嚴格遵守資料保護條例。濫用或洩露健康資料可能會損害公眾對診斷服務的信任。關於捐贈者知情同意和器官分配的倫理爭議可能會影響市場接受度。區域監管差異給跨國診斷服務提供者帶來了複雜的挑戰。安全的資料儲存和遵守隱私標準會增加營運成本。這些因素可能會減緩某些市場對先進移植診斷技術的採用。

新冠疫情的感染疾病：

檢查室運作面臨臨時關閉和人員短缺，影響了檢體處理。診斷劑和試劑盒的全球供應鏈中斷，限制了檢測的可用性。遠端醫療和遠端監測被迅速採用，以維持患者隨訪和移植後護理。監管機構加快了關鍵診斷工具的核准，以支援緊急情況。此次危機凸顯了建構具有韌性的供應鏈和分散式檢查網路的重要性。疫情後，移植診斷正著力於自動化、快速偵測和營運柔軟性，以防止未來再次中斷。

預測期內，分子檢測領域將佔據最大的市場佔有率。

由於分子檢測在檢測移植相關併發症具有高靈敏度和特異性，因此預計在預測期內，分子檢測領域將佔據最大的市場佔有率。這些檢測廣泛用於監測病毒感染、移植物排斥反應和免疫反應。多重PCR和次世代定序等技術進步拓展了其臨床效用。檢查室擴大採用分子檢測平台以加快檢測結果的周轉速度。這種趨勢的動力源自於人們對早期療育對移植患者益處的認知不斷提高。

在預測期內，參考實驗室細分市場將實現最高的複合年成長率。

由於其高通量和專業化的檢測能力，預計參考實驗室領域在預測期內將實現最高成長率。這些機構提供小規模醫院難以提供的先進診斷服務。對自動化平台和人工智慧輔助解讀的投資有助於提高效率和準確性。將診斷檢測外包給參考實驗室可以減輕移植中心的營運負擔。對複雜免疫學和基因組學檢測需求的不斷成長正在推動該領域的擴張。參考實驗室也正在擴大其全球企業發展，以滿足新興市場的需求。

佔比最大的地區：

由於北美擁有先進的醫療基礎設施和對創新診斷技術的積極應用，預計在預測期內將佔據最大的市場佔有率。美國和加拿大擁有完善的移植網路和專業實驗室。人們對器官移植排斥風險的高度重視推動了檢測需求的成長。研發投入和監管支持促進了新型檢測方法的開發和商業化。學術機構與診斷公司之間的策略合作也十分普遍。該地區受益於健全的健保報銷體系，這鼓勵了診斷技術的廣泛應用。

預計年複合成長率最高的地區：

預計亞太地區在預測期內將實現最高的複合年成長率，這主要得益於醫療基礎設施的不斷改進和器官移植項目的日益增加。中國、印度和日本等國家正大力投資建造現代化實驗室和診斷技術。慢性病發病率的上升和人們對移植監測意識提升，推動了市場需求的成長。政府主導的措施正在支持本地生產和技術轉移。國際合作使得先進的分子和免疫學檢測技術得以應用。人工智慧診斷平台的快速普及提高了檢測的準確性。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，對主要國家進行市場估算和預測，並計算複合年成長率（註：可行性需確認）。
  • 競爭標竿分析
    • 基於產品系列、地域覆蓋範圍和策略聯盟對主要參與者進行基準分析

目錄

第1章執行摘要

第2章 前言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球移植診斷市場（依檢測類型分類）

  • 分子檢測
    • 基於PCR的檢測
    • 即時PCR
    • 次世代定序（NGS）
    • 桑格定序
  • 非分子檢測
    • 血清學檢測
    • 混合淋巴球培養
  • 基於定序的分子檢測

6. 全球移植診斷市場（依生物標記類型分類）

  • 裝置
  • 基因生物標記
  • 蛋白質體學生物標記
  • 細胞生物標記
  • 代謝體學物標誌物

7. 全球移植診斷市場（依移植類型分類）

  • 腎臟移植
  • 肝臟移植
  • 心臟移植
  • 肺移植
  • 骨髓移植
  • 其他

8. 全球移植診斷市場（按應用分類）

  • 人類白血球抗原（HLA）檢測
  • 血液檢查
  • 病原體檢測
  • 交叉配對試驗
  • 其他

9. 全球移植診斷市場（以最終用戶分類）

  • 醫院和診所
  • 診斷檢查室
  • 研究和學術機構
  • 參考檢查室
  • 其他

第10章 全球移植診斷市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 企業概況

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Illumina, Inc.
  • QIAGEN NV
  • Bio-Rad Laboratories, Inc.
  • Becton, Dickinson and Company
  • Immucor, Inc.
  • CareDx, Inc.
  • Omixon Inc.
  • Hologic, Inc.
  • Adaptive Biotechnologies Corporation
  • NanoString Technologies, Inc.
  • Eurofins Viracor
  • GenDx
Product Code: SMRC33391

According to Stratistics MRC, the Global Transplant Diagnostics Market is accounted for $6.99 billion in 2025 and is expected to reach $13.11 billion by 2032 growing at a CAGR of 9.4% during the forecast period. Transplant diagnostics is a medical discipline focused on examining and monitoring the health and compatibility of transplanted organs or tissues. It encompasses testing to ensure donor-recipient matching, tracking organ functionality, and identifying potential rejection or infections at an early stage. Through precise and prompt assessments, this field assists healthcare providers in enhancing patient outcomes, prolonging graft longevity, and minimizing complications.

According to the Health Resources & Services Administration (HRSA), as of March 2024, more than 46,000 organ transplants were performed in the U.S.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

Healthcare providers are seeking precise testing methods to optimize donor-recipient matching and improve patient outcomes. Innovations in molecular and immunological assays are allowing earlier detection of transplant complications. Aging populations and rising comorbidity rates are expanding the need for diagnostic monitoring post-transplant. Hospitals and specialized clinics are adopting cutting-edge diagnostic platforms to reduce rejection risks. The growth of personalized medicine is encouraging the use of tailored diagnostic panels for each patient. Overall, the surge in chronic disease prevalence is accelerating the adoption of sophisticated transplant diagnostic solutions.

Restraint:

Organ shortage gap

Limited organ availability increases the pressure on diagnostic workflows to maximize graft success. Regulatory hurdles and strict ethical guidelines further complicate donor matching processes. Small laboratories and emerging market facilities often face resource constraints that restrict adoption of advanced tests. Prolonged approval timelines for new diagnostic kits delay clinical implementation. These limitations may hinder investment in innovative technologies despite clinical need. As a result, the organ supply-demand gap continues to restrain the expansion of the transplant diagnostics market.

Opportunity:

AI and machine learning

Predictive algorithms can enhance donor-recipient compatibility assessments and forecast graft survival. Automated data analysis reduces diagnostic errors and accelerates decision-making in transplant centers. Machine learning models are increasingly applied to interpret complex immunological and genomic datasets. Adoption of AI-driven platforms allows laboratories to improve efficiency while reducing operational costs. Cloud-based analytics facilitate real-time monitoring of transplant patients across multiple facilities. This trend is expected to transform transplant diagnostics by enabling precision medicine and predictive care solutions.

Threat:

Ethical & data privacy concerns

The handling of sensitive genomic and immunological information requires strict compliance with data protection regulations. Misuse or breaches of health data could erode trust in diagnostic services. Ethical debates around donor consent and organ allocation may affect market acceptance. Regulatory differences across regions create complexities for multinational diagnostic providers. Ensuring secure data storage and adherence to privacy standards increases operational costs. These concerns could slow the adoption of advanced transplant diagnostic technologies in some markets.

Covid-19 Impact:

Laboratory operations faced temporary closures and staffing shortages, affecting sample processing. Global supply chains for diagnostic reagents and kits experienced interruptions, limiting test availability. Telemedicine and remote monitoring were rapidly adopted to maintain patient follow-up and post-transplant care. Regulatory authorities introduced expedited approvals for critical diagnostic tools to support urgent cases. The crisis highlighted the need for resilient supply chains and decentralized laboratory networks. Post-pandemic, transplant diagnostics are focusing on automation, rapid testing, and operational flexibility to prevent future disruptions.

The molecular assays segment is expected to be the largest during the forecast period

The molecular assays segment is expected to account for the largest market share during the forecast period, due to their high sensitivity and specificity in detecting transplant-related complications. These assays are widely used for monitoring viral infections, graft rejection, and immune response. Technological advancements, such as multiplex PCR and next-generation sequencing, are expanding their clinical utility. Laboratories are increasingly implementing molecular platforms for faster turnaround times. Adoption is driven by growing awareness of early intervention benefits for transplant patients.

The reference labs segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the reference labs segment is predicted to witness the highest growth rate, due to their capacity for high-throughput and specialized testing. These facilities provide advanced diagnostic services that smaller hospitals may lack. Investments in automated platforms and AI-assisted interpretation improve efficiency and accuracy. Outsourcing diagnostic testing to reference labs reduces operational burdens for transplant centers. Rising demand for complex immunological and genomic testing is driving expansion. Reference labs are also expanding their global footprint to cater to emerging markets.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to its advanced healthcare infrastructure and strong adoption of innovative diagnostics. The U.S. and Canada have well-established transplant networks and specialized laboratories. High awareness of organ rejection risks is driving demand for sophisticated testing. Investment in R&D and regulatory support encourage development and commercialization of new assays. Strategic collaborations between academic centers and diagnostic companies are common. The region benefits from robust reimbursement frameworks that facilitate widespread diagnostic adoption.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by expanding healthcare infrastructure and increasing organ transplant programs. Countries like China, India, and Japan are investing heavily in modern laboratories and diagnostic technologies. Growing incidence of chronic diseases and rising awareness of transplant monitoring is boosting demand. Government initiatives are supporting local manufacturing and technology transfer. International collaborations are enabling access to advanced molecular and immunological assays. Rapid adoption of AI-enabled diagnostic platforms is enhancing testing accuracy.

Key players in the market

Some of the key players in Transplant Diagnostics Market include Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Illumina, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Immucor, Inc., CareDx, Inc., Omixon Inc., Hologic, Inc., Adaptive Biotechnologies Corporation, NanoString Technologies, Inc., Eurofins Viracor, and GenDx.

Key Developments:

In January 2026, Thermo Fisher Scientific Inc. announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale. The effort will leverage the NVIDIA Artificial Intelligence (AI) platform and Thermo Fisher Scientific solutions to progressively increase the automation, accuracy and speed of laboratories. The companies are working together to evolve the digital foundation that powers scientific instruments, laboratory infrastructure and data.

In January 2026, Abbott announced a collaboration with AtaCor Medical to advance a next-generation investigational extravascular implantable cardioverter defibrillator (EV-ICD) system designed to deliver defibrillation therapy to people with life-threatening heart rhythms. Through the collaboration, AtaCor's investigational parasternal EV-ICD lead (Atala(TM)) will be paired with Abbott's investigational ICD system.

Test Types Covered:

  • Molecular Assays
  • Non-Molecular Assays
  • Sequencing-based Molecular Assays

Biomarker Types Covered:

  • Instruments
  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Cellular Biomarkers
  • Metabolomic Biomarkers

Transplant Types Covered:

  • Kidney Transplant
  • Liver Transplant
  • Heart Transplant
  • Lung Transplant
  • Bone Marrow Transplant
  • Other Organ Transplants

Applications Covered:

  • Human Leukocyte Antigen (HLA) Testing
  • Blood Profile Testing
  • Pathogen Detection
  • Crossmatching
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutes
  • Reference Labs
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Transplant Diagnostics Market, By Test Type

  • 5.1 Introduction
  • 5.2 Molecular Assays
    • 5.2.1 PCR-based assays
    • 5.2.2 Real-time PCR
    • 5.2.3 Next-Generation Sequencing (NGS)
    • 5.2.4 Sanger Sequencing
  • 5.3 Non-Molecular Assays
    • 5.3.1 Serological Assays
    • 5.3.2 Mixed Lymphocyte Culture
  • 5.4 Sequencing-based Molecular Assays

6 Global Transplant Diagnostics Market, By Biomarker Type

  • 6.1 Introduction
  • 6.2 Instruments
  • 6.3 Genomic Biomarkers
  • 6.4 Proteomic Biomarkers
  • 6.5 Cellular Biomarkers
  • 6.6 Metabolomic Biomarkers

7 Global Transplant Diagnostics Market, By Transplant Type

  • 7.1 Introduction
  • 7.2 Kidney Transplant
  • 7.3 Liver Transplant
  • 7.4 Heart Transplant
  • 7.5 Lung Transplant
  • 7.6 Bone Marrow Transplant
  • 7.7 Other Organ Transplants

8 Global Transplant Diagnostics Market, By Application

  • 8.1 Introduction
  • 8.2 Human Leukocyte Antigen (HLA) Testing
  • 8.3 Blood Profile Testing
  • 8.4 Pathogen Detection
  • 8.5 Crossmatching
  • 8.6 Other Applications

9 Global Transplant Diagnostics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Research & Academic Institutes
  • 9.5 Reference Labs
  • 9.6 Other End Users

10 Global Transplant Diagnostics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific, Inc.
  • 12.2 F. Hoffmann-La Roche Ltd.
  • 12.3 Abbott Laboratories
  • 12.4 Illumina, Inc.
  • 12.5 QIAGEN N.V.
  • 12.6 Bio-Rad Laboratories, Inc.
  • 12.7 Becton, Dickinson and Company
  • 12.8 Immucor, Inc.
  • 12.9 CareDx, Inc.
  • 12.10 Omixon Inc.
  • 12.11 Hologic, Inc.
  • 12.12 Adaptive Biotechnologies Corporation
  • 12.13 NanoString Technologies, Inc.
  • 12.14 Eurofins Viracor
  • 12.15 GenDx

List of Tables

  • Table 1 Global Transplant Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Transplant Diagnostics Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 3 Global Transplant Diagnostics Market Outlook, By Molecular Assays (2024-2032) ($MN)
  • Table 4 Global Transplant Diagnostics Market Outlook, By PCR-based assays (2024-2032) ($MN)
  • Table 5 Global Transplant Diagnostics Market Outlook, By Real-time PCR (2024-2032) ($MN)
  • Table 6 Global Transplant Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 7 Global Transplant Diagnostics Market Outlook, By Sanger Sequencing (2024-2032) ($MN)
  • Table 8 Global Transplant Diagnostics Market Outlook, By Non-Molecular Assays (2024-2032) ($MN)
  • Table 9 Global Transplant Diagnostics Market Outlook, By Serological Assays (2024-2032) ($MN)
  • Table 10 Global Transplant Diagnostics Market Outlook, By Mixed Lymphocyte Culture (2024-2032) ($MN)
  • Table 11 Global Transplant Diagnostics Market Outlook, By Sequencing-based Molecular Assays (2024-2032) ($MN)
  • Table 12 Global Transplant Diagnostics Market Outlook, By Biomarker Type (2024-2032) ($MN)
  • Table 13 Global Transplant Diagnostics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 14 Global Transplant Diagnostics Market Outlook, By Genomic Biomarkers (2024-2032) ($MN)
  • Table 15 Global Transplant Diagnostics Market Outlook, By Proteomic Biomarkers (2024-2032) ($MN)
  • Table 16 Global Transplant Diagnostics Market Outlook, By Cellular Biomarkers (2024-2032) ($MN)
  • Table 17 Global Transplant Diagnostics Market Outlook, By Metabolomic Biomarkers (2024-2032) ($MN)
  • Table 18 Global Transplant Diagnostics Market Outlook, By Transplant Type (2024-2032) ($MN)
  • Table 19 Global Transplant Diagnostics Market Outlook, By Kidney Transplant (2024-2032) ($MN)
  • Table 20 Global Transplant Diagnostics Market Outlook, By Liver Transplant (2024-2032) ($MN)
  • Table 21 Global Transplant Diagnostics Market Outlook, By Heart Transplant (2024-2032) ($MN)
  • Table 22 Global Transplant Diagnostics Market Outlook, By Lung Transplant (2024-2032) ($MN)
  • Table 23 Global Transplant Diagnostics Market Outlook, By Bone Marrow Transplant (2024-2032) ($MN)
  • Table 24 Global Transplant Diagnostics Market Outlook, By Other Organ Transplants (2024-2032) ($MN)
  • Table 25 Global Transplant Diagnostics Market Outlook, By Application (2024-2032) ($MN)
  • Table 26 Global Transplant Diagnostics Market Outlook, By Human Leukocyte Antigen (HLA) Testing (2024-2032) ($MN)
  • Table 27 Global Transplant Diagnostics Market Outlook, By Blood Profile Testing (2024-2032) ($MN)
  • Table 28 Global Transplant Diagnostics Market Outlook, By Pathogen Detection (2024-2032) ($MN)
  • Table 29 Global Transplant Diagnostics Market Outlook, By Crossmatching (2024-2032) ($MN)
  • Table 30 Global Transplant Diagnostics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 31 Global Transplant Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 32 Global Transplant Diagnostics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 33 Global Transplant Diagnostics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 34 Global Transplant Diagnostics Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 35 Global Transplant Diagnostics Market Outlook, By Reference Labs (2024-2032) ($MN)
  • Table 36 Global Transplant Diagnostics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.